Show simple item record

dc.contributor.advisorSkjeldestad, Finn-Egi
dc.contributor.advisorRevholt Pettersen, Åse Torunn
dc.contributor.authorGrönvall, Lina
dc.date.accessioned2022-08-10T09:37:10Z
dc.date.available2022-08-10T09:37:10Z
dc.date.issued2020-08-08en
dc.description.abstractBackground/Objective: There are major controversies in screening and diagnostic criteria for gestational diabetes. In 2017, new national guidelines were implemented in Norway. The aim of this study is to evaluate change in size of risk population for GDM, adherence to screening guidelines and follow up before and after implementation of the new guidelines. Method: This study is a retrospective case-series study. Data from women giving birth at the University Hospital of North Norway and the local maternity wards in Troms during first half-years of 2013 and 2018 was collected from the electronic medical record PARTUS and the antenatal fact sheet. Included were women giving birth after 29 weeks’ gestation, with singleton fetus and no pre-pregnancy DM (N=1349). Categorical variables were age (17-24, 25-34, 35-39 and 40 through highest), pre-pregnancy BMI (lowest thru 24.99, 25.00-26.99, 27.00 thru highest), parity (nulliparous/parous), ethnicity (high risk/low risk), follow up (neglected/lifestyle intervention/metformin/insulin), obstetric risk assessment (yes/no). Primary outcomes were change in size of risk population across guidelines, adherence to screening guidelines and prevalence of GDM. Statistical analyses were done using IBM SPSS with Chi-square test. P-values < 0.05 were considered statistically significant. Results: After changing the screening guidelines in 2017, the population at risk for GDM increased from 46.4% to 67.6% (p<0.01). However, only 28.7% in 2013 and 49.2% in 2018 were actually exposed to OGTT (p<0.01). Of those correctly screened 16.7% (15/90) of the women were diagnosed with GDM in 2013, respectively 10.7% (24/224) in 2018. Overall 2.2% (15/676) of the cohort was diagnosed with GDM in 2013 and 3.6% (24/673) in 2018. In 2018 41.7% of the women were diagnosed with GDM based on the fasting plasma glucose test solely. Among the women diagnosed with GDM, follow up was neglected in 13.3% in 2013, and in 20.8% in 2018. Of the remaining women, all women eligible for obstetric risk assessment in week 36 were followed-up as scheduled in the guidelines. Conclusion: With the introduction of new, broader criteria far more women were screened, resulting in a slightly higher prevalence of GDM. Adherence to screening guidelines remained poor across study populations. The national authorities in charge of screening for GDM need to consolidate quality measures that increase focus on screening and follow-up of women diagnosed with GDM.en_US
dc.identifier.urihttps://hdl.handle.net/10037/26050
dc.language.isoengen_US
dc.publisherUiT Norges arktiske universitetno
dc.publisherUiT The Arctic University of Norwayen
dc.rights.holderCopyright 2020 The Author(s)
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0en_US
dc.rightsAttribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)en_US
dc.subject.courseIDMED-3950
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Gynekologi og obstetrikk: 756en_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Gynecology and obstetrics: 756en_US
dc.titleAdherence to screening guidelines for gestational diabetes in pregnancyen_US
dc.typeMaster thesisen
dc.typeMastergradsoppgaveno


File(s) in this item

Thumbnail
Thumbnail

This item appears in the following collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)